MedTrace Logo

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

NCT05305989 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-05-02

Study results available
· View outcomes & findings →

Summary

Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213

Conditions

  • Chronic Graft-versus-host-disease

Interventions

DRUG

Belumosudil 200 mg QD

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

DRUG

Belumosudil 200 mg BID

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

DRUG

Belumosudil 400 mg QD

Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Sponsors & Collaborators

  • Kadmon, a Sanofi Company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-23
Primary Completion
2024-06-06
Completion
2024-06-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305989 on ClinicalTrials.gov